May 26, 2022 -- While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct the underlying genetic defect.
CRISPR is the "cut" function and Graphite Bio's technology is the "cut and paste" capability, Lehrer told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC.
"We have a slightly different approach where what we're trying to do is use CRISPR essentially as more than a pair of scissors. We're trying to build on CRISPR technology to get to very efficient, reproducible, precise cutting and pasting," Lehrer said.
The targeted approach is designed to precisely replace defective genes at their native chromosomal location, allowing for the production of normal gene expression within the inserted cells. Graphite Bio uses a CRISPR system to leverage a natural repair process of cells called homology-directed repair, without introducing any errors.
Watch the video below to learn more.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: